Physician profile
Adrian Dyer
NPI 1790280386
$5,045.13
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $2,245 · 2023: $1,925 · 2024: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.46 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $826.89 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $508.17 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Corcept Therapeutics | $359.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $276.69 | 2021-2024 | Farxiga, Breztri |
| Gilead Sciences, INC. | $207.50 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.17 | 2022-2024 | Jardiance |
| Abbott Laboratories | $162.53 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $148.05 | 2022-2024 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $131.51 | 2022-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $128.05 | 2022-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $123.90 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $120.02 | 2023 | Verquvo, Lagevrio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.31 | 2022-2024 | Caplyta |
| Pfizer INC. | $85.36 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.27 | 2021-2023 | Eliquis |
| Exact Sciences Corporation | $62.63 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $62.15 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.22 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $55.89 | 2023-2024 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $46.39 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $43.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.71 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.40 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $31.03 | 2022 | |
| Arcutis Biotherapeutics, INC. | $24.76 | 2023 | |
| Arbor Pharmaceuticals, INC. | $23.23 | 2022 | |
| Antares Pharma, INC. | $21.26 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.30 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.